Gracell Biotechnologies Stock Predictions

Healthcare > Biotechnology

Buy GRCL

*Your capital is at risk

$10.25

+0 (+0%)

At Close: May 20, 2024

Currently predicting for Mon, 8 Jun 2026

GRCL Prediction Chart

GRCL Predictions History

Latest community submissions for GRCL.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Kathy Pro	Aug 31, 2023	$3.39 -4.46%	$3.28	V	96.60%	1
PredictionBot.Warren Pro	Aug 31, 2023	$3.45 -2.79%	$3.28	V	94.79%	1
lemwink72.389539	Aug 31, 2023	Bullish	$3.28	X	—	0
PredictionBot.Kathy Pro	Jun 13, 2023	$4.62 -2.61%	$6.07	X	76.05%	0
PredictionBot.Warren Pro	Jun 13, 2023	$4.66 -1.63%	$6.07	X	76.81%	0
baycspmtlfldafbbmi	Jun 13, 2023	Bullish	$6.07	V	—	1

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for GRCL with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT GRACELL BIOTECHNOLOGIES INC.

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate,...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
FISV	0%	Nov 30
K KEEL	0%	Nov 30
D DFTX	0%	Nov 30
R RKLZ	0%	Nov 30
R RKTO	0%	Nov 30

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by